Elevated levels of IL-6 are believed to be causal factors in PTSD, Chronic Traumatic Encephalopathy, & Alzheimer's Disease.
JACKSON CENTER, PA / ACCESSWIRE / November 1, 2021 / Halberd Corporation (OTC PINK:HALB) successfully eradicated 100% of IL-6 from synthetic cerebral spinal fluid (CSF) in preliminary testing. Through its patented extracorporeal process in combination with its patent-pending laser eradication process, IL-6 was virtually eliminated in as little as three minutes of laser radiation exposure. Elevated levels of IL-6 in CSF have been linked to various neurological disorders.
Dr. Mitchell S. Felder, Chief Technology Officer of Halberd Corporation and a board certified attending neurologist remarked, "The spontaneous production of IL-6 has been shown to be significantly higher in PTSD patients. This has directly correlated with PTSD symptom severity within the PTSD patient group. Practicing psychiatrists have stated they believe that the precisely controlled elimination of IL-6 and other inflammatory cytokines in CSF (cerebrospinal fluid) could be a very major breakthrough against PTSD and suicidal depression. Our recent breakthrough historic achievements with our university partners, position us to achieve that goal in medical practice."
William A. Hartman, Halberd Corporation's Chairman, President & CEO, added, "This is the next step in our march towards finding effective treatments for PTSD, CTE and Alzheimer's Disease. Previously, we successfully eliminated Phosphorylated Tau from CSF, the primary building block of neurofibrillary tangles associated with Alzheimer's Disease. Now that the quality problems have been eliminated from our purchased materials, we expect rapid progress ahead toward the final steps with these historic accomplishments.
"The next steps in our research program include verification testing related to IL-6 elimination from CSF, then moving on to eliminating Tumor Necrosis Factor - Alpha (TNF-α) and ultimately Glutamate from CSF. When we successfully eliminate these pathogens, we will approach the military for endorsement/support. Meanwhile, our longer term objective is to continue to focus on the eradication of the remaining pathogens from CSF and blood plasma related to Alzheimer's Disease, Parkinson's Disease, Lou Gehrig's Disease, Epilepsy and Obesity."
To get the latest news on Halberd's exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC
About Halberd Corporation.
Halberd Corporation (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It holds the exclusive worldwide rights to numerous patent- and PCT-pending extracorporeal treatments for COVID-19, PTSD, Alzheimer's Disease, and other medical maladies. Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287 and an allowed but not yet issued patent for the treatment of Cockayne Syndrome.
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Company cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Company undertakes no obligation to revise these statements following the date of this news release.
Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives -
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis. The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment, or other strategies with regard to COVID-19.
The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.
We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders."
SOURCE: Halberd Corporation
View source version on accesswire.com:
https://www.accesswire.com/670491/Halberd-Successfully-Eradicates-IL-6-a-Critical-Factor-in-PTSD-CTE-Alzheimers-Disease
